# Sunshine Biopharma Inc.: financial statements, quarterly

SBFM · Nasdaq · CIK 1402328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sbfm.md) · [Financials](/companies/sbfm/financials.md) · [Filings](/companies/sbfm/filings.md) · [Insiders](/companies/sbfm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sbfm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [5,958](/filings/0001683168-24-007622.md) | [7,680 d](/filings/0001683168-25-002184.md) | [7,541](/filings/0001683168-25-003701.md) | [9,303](/filings/0001683168-25-005981.md) | [8,435](/filings/0001683168-25-008328.md) | [9,595 d](/filings/0001683168-26-002644.md) | [8,901](/filings/0001683168-26-003819.md) | [9,410](/filings/0001683168-26-006340.md) | [9,417](/filings/0001683168-25-008328.md) | [8,577 d](/filings/0001683168-26-002644.md) | [8,089](/filings/0001683168-26-003819.md) | [9,264](/filings/0001683168-26-006340.md) |
| Cost of revenue | $k | [3,967](/filings/0001683168-24-007622.md) | [5,112 d](/filings/0001683168-25-002184.md) | [5,187](/filings/0001683168-25-003701.md) | [6,947](/filings/0001683168-25-005981.md) | [5,569](/filings/0001683168-25-008328.md) | [6,502 d](/filings/0001683168-26-002644.md) | [6,171](/filings/0001683168-26-003819.md) | [5,987](/filings/0001683168-26-006340.md) | [6,344](/filings/0001683168-25-008328.md) | [5,548 d](/filings/0001683168-26-002644.md) | [5,908](/filings/0001683168-26-003819.md) | [6,837](/filings/0001683168-26-006340.md) |
| Gross profit | $k | [1,990](/filings/0001683168-24-007622.md) | [2,568 d](/filings/0001683168-25-002184.md) | [2,354](/filings/0001683168-25-003701.md) | [2,356](/filings/0001683168-25-005981.md) | [2,866](/filings/0001683168-25-008328.md) | [3,093 d](/filings/0001683168-26-002644.md) | [2,730](/filings/0001683168-26-003819.md) | [3,423](/filings/0001683168-26-006340.md) | [3,074](/filings/0001683168-25-008328.md) | [3,029 d](/filings/0001683168-26-002644.md) | [2,181](/filings/0001683168-26-003819.md) | [2,427](/filings/0001683168-26-006340.md) |
| Research and development | $k | [238](/filings/0001683168-24-007622.md) | [816 d](/filings/0001683168-25-002184.md) | [222](/filings/0001683168-25-003701.md) | [436](/filings/0001683168-25-005981.md) | [126](/filings/0001683168-25-008328.md) | [149 d](/filings/0001683168-26-002644.md) | [215](/filings/0001683168-26-003819.md) | [196](/filings/0001683168-26-006340.md) | [119](/filings/0001683168-25-008328.md) | [73.5 d](/filings/0001683168-26-002644.md) | [31.7](/filings/0001683168-26-003819.md) | [13.2](/filings/0001683168-26-006340.md) |
| Operating income | $k | [(779)](/filings/0001683168-24-007622.md) | [(1,187) d](/filings/0001683168-25-002184.md) | [(1,351)](/filings/0001683168-25-003701.md) | [(1,268)](/filings/0001683168-25-005981.md) | [(1,106)](/filings/0001683168-25-008328.md) | [(2,038) d](/filings/0001683168-26-002644.md) | [(1,296)](/filings/0001683168-26-003819.md) | [(2,055)](/filings/0001683168-26-006340.md) | [(1,087)](/filings/0001683168-25-008328.md) | [(1,790) d](/filings/0001683168-26-002644.md) | [(1,396)](/filings/0001683168-26-003819.md) | [(1,613)](/filings/0001683168-26-006340.md) |
| Interest expense | $k | [38.5](/filings/0001683168-23-007911.md) | [30.1 d](/filings/0001683168-24-001818.md) | [49.2](/filings/0001683168-24-003688.md) | [0.2](/filings/0001683168-25-005981.md) | [0.0](/filings/0001683168-25-008328.md) | [8.5 d](/filings/0001683168-26-002644.md) | [0.0](/filings/0001683168-25-003701.md) | [0.0](/filings/0001683168-25-005981.md) | [0.0](/filings/0001683168-25-008328.md) | [0.0 d](/filings/0001683168-26-002644.md) | not reported | not reported |
| Income tax | $k | [41.0](/filings/0001683168-24-007622.md) | [220 d](/filings/0001683168-25-002184.md) | [22.4](/filings/0001683168-25-003701.md) | [(344)](/filings/0001683168-25-005981.md) | [215](/filings/0001683168-25-008328.md) | [(129) d](/filings/0001683168-26-002644.md) | [(40.2)](/filings/0001683168-26-003819.md) | [(209)](/filings/0001683168-26-006340.md) | [(137)](/filings/0001683168-25-008328.md) | [408 d](/filings/0001683168-26-002644.md) | [0.0](/filings/0001683168-26-003819.md) | [0.0](/filings/0001683168-26-006340.md) |
| Net income | $k | [(651)](/filings/0001683168-24-007622.md) | [(1,250) d](/filings/0001683168-25-002184.md) | [(1,284)](/filings/0001683168-25-003701.md) | [(494)](/filings/0001683168-25-005981.md) | [(1,198)](/filings/0001683168-25-008328.md) | [(2,158) d](/filings/0001683168-26-002644.md) | [(1,180)](/filings/0001683168-26-003819.md) | [(1,771)](/filings/0001683168-26-006340.md) | [(884)](/filings/0001683168-25-008328.md) | [(2,141) d](/filings/0001683168-26-002644.md) | [(1,244)](/filings/0001683168-26-003819.md) | [(1,564)](/filings/0001683168-26-006340.md) |
| Diluted EPS | $ per share | not reported | not reported | [(2.00)](/filings/0001683168-25-003701.md) | [(43.48)](/filings/0001683168-25-005981.md) | not reported | not reported | [(0.44)](/filings/0001683168-25-003701.md) | [(0.82)](/filings/0001683168-25-005981.md) | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(50.72)](/filings/0001683168-24-007622.md) | not reported | [(2.00)](/filings/0001683168-25-003701.md) | [(9.94)](/filings/0001683168-25-005981.md) | [(0.94)](/filings/0001683168-25-008328.md) | not reported | [(0.44)](/filings/0001683168-26-003819.md) | [(3.94)](/filings/0001683168-26-006340.md) | [(0.19)](/filings/0001683168-25-008328.md) | not reported | [(0.25)](/filings/0001683168-26-003819.md) | [(1.15)](/filings/0001683168-26-006340.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [25.4](/filings/0001683168-23-007911.md) | [24.9](/filings/0001683168-25-002184.md) | [28.8](/filings/0001683168-24-003688.md) | [25.7](/filings/0001683168-24-005931.md) | [26.0](/filings/0001683168-24-007622.md) | [26.0](/filings/0001683168-26-002644.md) | [24.5](/filings/0001683168-25-003701.md) | [27.9](/filings/0001683168-25-005981.md) | [28.0](/filings/0001683168-25-008328.md) | [26.9](/filings/0001683168-26-006340.md) | [24.8](/filings/0001683168-26-003819.md) | [30.7](/filings/0001683168-26-006340.md) |
| Total assets | $m | [27.7](/filings/0001683168-23-007911.md) | [27.3](/filings/0001683168-25-002184.md) | [31.9](/filings/0001683168-24-003688.md) | [29.3](/filings/0001683168-24-005931.md) | [30.1](/filings/0001683168-24-007622.md) | [30.6](/filings/0001683168-26-002644.md) | [29.2](/filings/0001683168-25-003701.md) | [32.0](/filings/0001683168-25-005981.md) | [31.5](/filings/0001683168-25-008328.md) | [30.1](/filings/0001683168-26-006340.md) | [27.9](/filings/0001683168-26-003819.md) | [33.6](/filings/0001683168-26-006340.md) |
| Current liabilities | $m | [5.1](/filings/0001683168-23-007911.md) | [5.6](/filings/0001683168-25-002184.md) | [6.5](/filings/0001683168-24-003688.md) | [5.3](/filings/0001683168-24-005931.md) | [4.5](/filings/0001683168-24-007622.md) | [6.3](/filings/0001683168-26-002644.md) | [5.8](/filings/0001683168-25-003701.md) | [5.6](/filings/0001683168-25-005981.md) | [6.7](/filings/0001683168-25-008328.md) | [6.4](/filings/0001683168-26-006340.md) | [5.9](/filings/0001683168-26-003819.md) | [5.6](/filings/0001683168-26-006340.md) |
| Total liabilities | $m | [5.7](/filings/0001683168-23-007911.md) | [6.1](/filings/0001683168-25-002184.md) | [7.1](/filings/0001683168-24-003688.md) | [5.8](/filings/0001683168-24-005931.md) | [5.0](/filings/0001683168-24-007622.md) | [7.1](/filings/0001683168-26-002644.md) | [6.5](/filings/0001683168-25-003701.md) | [6.3](/filings/0001683168-25-005981.md) | [7.3](/filings/0001683168-25-008328.md) | [7.0](/filings/0001683168-26-006340.md) | [6.4](/filings/0001683168-26-003819.md) | [6.1](/filings/0001683168-26-006340.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [22.0](/filings/0001683168-24-007622.md) | [21.2](/filings/0001683168-26-002644.md) | [24.8](/filings/0001683168-25-005981.md) | [23.5](/filings/0001683168-25-008328.md) | [25.0](/filings/0001683168-25-008328.md) | [23.5](/filings/0001683168-26-006340.md) | [22.7](/filings/0001683168-26-006340.md) | [25.7](/filings/0001683168-26-006340.md) | [24.2](/filings/0001683168-25-008328.md) | [23.0](/filings/0001683168-26-006340.md) | [21.5](/filings/0001683168-26-006340.md) | [27.5](/filings/0001683168-26-006340.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(457) d](/filings/0001683168-24-007622.md) | [(2,690) d](/filings/0001683168-25-002184.md) | [(3,185)](/filings/0001683168-25-003701.md) | [(4,578) d](/filings/0001683168-25-005981.md) | [(1,357) d](/filings/0001683168-25-008328.md) | [(3,405) d](/filings/0001683168-26-002644.md) | [(1,695)](/filings/0001683168-26-003819.md) | [(1,273) d](/filings/0001683168-26-006340.md) | [(747) d](/filings/0001683168-25-008328.md) | [(1,616) d](/filings/0001683168-26-002644.md) | [(2,072)](/filings/0001683168-26-003819.md) | [(918) d](/filings/0001683168-26-006340.md) |
| Capital expenditure | $k | [9.6 d](/filings/0001683168-24-007622.md) | [(382) d](/filings/0001683168-25-002184.md) | [62.9](/filings/0001683168-25-003701.md) | [975 d](/filings/0001683168-25-005981.md) | [517 d](/filings/0001683168-25-008328.md) | [103 d](/filings/0001683168-26-002644.md) | [7.5](/filings/0001683168-26-003819.md) | [160 d](/filings/0001683168-26-006340.md) | [8.0 d](/filings/0001683168-25-008328.md) | [(1.0) d](/filings/0001683168-26-002644.md) | [5.1](/filings/0001683168-26-003819.md) | [7.0 d](/filings/0001683168-26-006340.md) |
| Share repurchases | $k | not reported | [0.0 d](/filings/0001683168-25-002184.md) | [3,140](/filings/0001683168-25-003701.md) | [0.0 d](/filings/0001683168-25-005981.md) | [0.0 d](/filings/0001683168-25-008328.md) | [0.0 d](/filings/0001683168-26-002644.md) | [0.0](/filings/0001683168-25-003701.md) | [0.0 d](/filings/0001683168-25-005981.md) | [0.0 d](/filings/0001683168-25-008328.md) | [0.0 d](/filings/0001683168-26-002644.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [5.3](/filings/0001683168-23-003121.md) | [15.8](/filings/0001683168-23-005518.md) | [18.9](/filings/0001683168-23-007911.md) | [0.2](/filings/0001683168-24-003688.md) | [0.0](/filings/0001683168-24-005931.md) | [0.0](/filings/0001683168-24-007622.md) | [0.6](/filings/0001683168-25-003701.md) | [0.0](/filings/0001683168-25-005981.md) | [1.3](/filings/0001683168-24-007622.md) | [2.7](/filings/0001683168-25-003701.md) | [3.6](/filings/0001683168-25-005981.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,877,337 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001683168-26-006340.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.